NCT00001042View on ClinicalTrials.gov

A Phase I, Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Compare the Safety and Immunogenicity of Recombinant Envelope Protein rgp120/HIV-1SF2 (BIOCINE) Combined With Seven Adjuvants in Healthy HIV-1 Uninfected Individuals

PHASE1CompletedINTERVENTIONAL
Enrollment

112

Participants

Timeline

Start Date

Not specified

Study Completion Date

March 31, 1996

Conditions
HIV Infections
Interventions
BIOLOGICAL

Aluminum hydroxide

BIOLOGICAL

Lipid A, Monophosphoryl

BIOLOGICAL

Lipid A, Liposome-encapsulated monophosphoryl

BIOLOGICAL

Syntex adjuvant formulation

BIOLOGICAL

MF59

BIOLOGICAL

Threonyl Muramyl Dipeptide

BIOLOGICAL

rgp120/HIV-1 SF-2

BIOLOGICAL

MTP-PE/MF59

Trial Locations (3)

14642

Univ. of Rochester AVEG, Rochester

63104

St. Louis Univ. School of Medicine AVEG, St Louis

98144

UW - Seattle AVEG, Seattle

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00001042 - A Phase I, Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Compare the Safety and Immunogenicity of Recombinant Envelope Protein rgp120/HIV-1SF2 (BIOCINE) Combined With Seven Adjuvants in Healthy HIV-1 Uninfected Individuals | Biotech Hunter | Biotech Hunter